诺为泰（Novotech）：2025特发性肺纤维化（IPF）：全球临床试验概况报告（英文版）（20页）.pdf

1、novotech-2025IPF-Global Clinical Trial LandscapeEmerging therapies reshape IPF treatment through RNAi,AI-de-signed drugs,prostacy-clin analogs,and path-way inhibitors targeting fibrosis,inflammation,and disease progressionThe U.S.and Switzerland led IPF venture funding,with contributions from China,

2、South Korea,Japan,and IndiaCountries Mainland China,the United States,Australia,and the United Kingdom,emerged as top locations for conducting trialsBiomarkers are key to early,accurate IPF diagnosis and personalized treatment,advancing precision medicine in patient careIDIOPATHIC PULMONARY FIBROSIS

3、(IPF)TRIAL CONTRIBUTIONSIPF is a progressive lung disease marked by lung tissue scarring and declining respiratory functionThe content of this publication is proprietary to Novotech Health Holdings.No part of this publication may be reproduced,distributed,or transmitted in any form or by any means,i

4、ncluding photocopying,recording,or other electronic or mechanical methods,without the prior written permission of Novotech except in the case of quotations embodied in reviews and non-commercial uses.Please note that this copyright statement applies specifically to this publication and its content a

5、nd does not extend to other materials or intellectual property owned by Novotech.Any unauthorized reproduction or distribution of this publication or any portion thereof may result in legal action taken by Novotech to protect its rights.For permissions or inquiries,please contact:communicationsnovot

6、ech-IDIOPATHIC PULMONARY FIBROSIS(IPF)GLOBAL CLINICAL TRIAL LANDSCAPE(2025)#DYK Did youknow?The Asia-Pacific region showed variation,with South Korea reporting the highest incidenceIn North America,Canada recorded the highest inci-dence and prevalence of IPFIn Europe,Italy and France were among the